Autolus Therapeutics plc (AUTL): Net Income
-$287.53M
Year ended 2025-12-31
-$280.16M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$287.53M | n/m | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | -$220.66M | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$208.38M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$148.84M | n/m | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | -$142.10M | n/m | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | -$142.09M | n/m | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | -$123.85M | n/a | 2022-03-10, From 2019-01-01 |
| No annual figure between 2018-09-30 and 2019-12-31. | |||
| 2018-09-30 | -$44.75M | n/m | 2021-03-04, From 2017-10-01 |
| 2017-09-30 | -$19.73M | n/m | 2020-03-03, From 2016-10-01 |
| 2016-09-30 | -$12.55M | n/a | 2019-02-25, From 2015-10-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$287.53M | n/m |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | -$644.76M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $35.34M | n/m |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $22.37M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$114.20M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$437.99M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | -$140.11M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.18M | n/m |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$191.09M | n/m |
Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗